Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

PROSHARES TRUST (ZBIO) EBIT: 2023-2025

Historic EBIT for Zenas BioPharma (ZBIO) over the last 2 years, with Sep 2025 value amounting to -$52.6 million.

  • Zenas BioPharma's EBIT fell 28.29% to -$52.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$200.7 million, marking a year-over-year decrease of 50.85%. This contributed to the annual value of -$163.9 million for FY2024, which is 341.19% down from last year.
  • According to the latest figures from Q3 2025, Zenas BioPharma's EBIT is -$52.6 million, which was up 4.68% from -$55.2 million recorded in Q2 2025.
  • Zenas BioPharma's EBIT's 5-year high stood at $35.6 million during Q3 2023, with a 5-year trough of -$55.6 million in Q4 2024.
  • Over the past 3 years, Zenas BioPharma's median EBIT value was -$39.7 million (recorded in 2024), while the average stood at -$33.1 million.
  • Data for Zenas BioPharma's EBIT shows a maximum YoY slumped of 215.05% (in 2024) over the last 5 years.
  • Over the past 3 years, Zenas BioPharma's EBIT (Quarterly) stood at -$24.8 million in 2023, then slumped by 124.48% to -$55.6 million in 2024, then fell by 28.29% to -$52.6 million in 2025.
  • Its EBIT was -$52.6 million in Q3 2025, compared to -$55.2 million in Q2 2025 and -$37.3 million in Q1 2025.